Trial reportMolecular nutrition & food research2026
Tannin Phytocomplex Improves IBS-D Symptoms and Gut-Brain Markers: Prospective Pilot Study.
Trial report in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05207618 (Utility of the Administration of Tannin Specific Natural Extract, Chesnut and Quebracho Based, for Irritable Bowel Syndrome Diarrhea Predominant), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of the Administration of Tannin Specific Natural Extract, Chesnut and Quebracho Based, for Irritable Bowel Syndrome Diarrhea Predominant
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a multifactorial disorder involving gut-brain axis dysregulation, altered barrier integrity, microbial imbalance, and stress-related mechanisms, with limited nutritional strategies targeting these pathways. Tannin-rich extracts may exert barrier-protective, microbiota-modulating, and stress-related effects. In a prospective before-after pilot study (NCT05207618), 28 adults with IBS‑D completed a 60‑day tannin-based supplementation (480 mg/day). Outcomes included IBS Severity Scoring System (IBS-SSS), bowel habits, somatization, perceived stress, serum zonulin, faecal short-chain fatty acids, and hydrogen breath test. Linear mixed models assessed changes over time. IBS-SSS decreased by an estimated mean of 70 points (95% CI: 34-107; p < 0.0001); stool consistency improved by 1.38 (95% CI: 0.72 to 2.05; p < 0.0001), and bowel movements/day decreased by 0.84 (95% CI: 0.08 to 1.71; P = 0.028). Somatization and stress scores declined significantly (both P ≤ 0.003). Zonulin dropped (P < 0.0001), butyrate increased (p = 0.001), and propionate decreased (p = 0.017). Hydrogen-positive subjects at baseline (3/28) were all negative at 60 days. No adverse events occurred. This pilot suggests a tannin-based phytocomplex may improve gastrointestinal and psychological symptoms in IBS-D, with biomarker changes indicating enhanced barrier function and microbial metabolism. Larger trials are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.